Effect of transforming growth factor-beta on activity of connective tissue growth factor gene promoter in mouse NIH/3T3 fibroblasts

Acta Pharmacol Sin. 2004 Apr;25(4):485-9.

Abstract

Aim: To investigate the regulatory mechanism of transforming growth factor-beta on activity of connective tissue growth factor promoter in mouse NIH/3T3 fibroblasts.

Methods: The regulation fragment of the 5' flanking region of the human CTGF gene was linked to pGL3-Basic vector, a firefly luciferase reporter construct without promoter. The recombinant plasmid pCTGF-luc was transiently transfected to NIH/3T3 fibroblasts. The activity of CTGF promoter after treatment of TGF-beta(1) and MAPK pathway inhibitors were assayed with luciferase reporter gene assay system.

Results: TGF-beta(1)-induced increase of CTGF promoter activity was concentration-dependent, with a plateau at 5 microg/L by 2.67-fold vs control (P<0.05). The TGF-beta(1) stimulation of CTGF promoter activity was time-dependent, too. After exposure to TGF-beta(1) (5 microg/L), the maximal level of luciferase activity was reached at 12 h and maintained to 24 h by 2.76- and 2.20-fold vs control, respectively (P<0.05). Blockade of MAPK pathway with PD98059 (10 micromol/L), the MAP kinase kinase 1 inhibitor, and SB203580 (10 micromol/L), the p38 MAP kinase inhibitor, decreased basal and TGF-beta (1)-induced activation of CTGF promoter. However, inhibition of c-Jun-N-terminal kinase/stress-activated protein kinase by SP600125 (20 micromol/L) was without effect.

Conclusion: TGF-beta(1) stimulated the transcriptional activity of CTGF gene promoter in NIH/3T3 fibroblasts in a dose- and time-dependent manner. MAPK pathway may play a role in the regulation of TGF-beta(1)-induced CTGF expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Connective Tissue Growth Factor
  • Dose-Response Relationship, Drug
  • Flavonoids / pharmacology
  • Imidazoles / pharmacology
  • Immediate-Early Proteins / genetics
  • Immediate-Early Proteins / metabolism*
  • Intercellular Signaling Peptides and Proteins / genetics
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Luciferases / genetics
  • Luciferases / metabolism*
  • MAP Kinase Kinase 1
  • MAP Kinase Signaling System*
  • Mice
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • NIH 3T3 Cells
  • Promoter Regions, Genetic / drug effects
  • Pyridines / pharmacology
  • Time Factors
  • Transcription, Genetic
  • Transforming Growth Factor beta / administration & dosage
  • Transforming Growth Factor beta / pharmacology*
  • Transforming Growth Factor beta1
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • CCN2 protein, human
  • CCN2 protein, mouse
  • Flavonoids
  • Imidazoles
  • Immediate-Early Proteins
  • Intercellular Signaling Peptides and Proteins
  • Pyridines
  • TGFB1 protein, human
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Connective Tissue Growth Factor
  • Luciferases
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • Map2k1 protein, mouse
  • Mitogen-Activated Protein Kinase Kinases
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one